Table 1 Associations of SLC14A1 expression with clinicopathological characteristics of PCa patients.

From: Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression

Characteristics

Total (N)

Odds ratio (OR)

p value

T stage (T3&T4 vs. T2)

488

0.638 (0.441–0.921)

0.017

N stage (N1 vs. N0)

422

0.504 (0.300–0.833)

0.008

M stage (M1 vs. M0)

456

0.511 (0.024–5.373)

0.585

Gleason score (9&10 vs. 6&7)

432

0.408 (0.268–0.616)

 < 0.001

Age (> 60 vs. <=60)

495

0.855 (0.600–1.219)

0.388

PSA (ng/mL) (>=4 vs. < 4)

438

0.552 (0.239–1.215)

0.148

Residual tumor (R1&R2 vs. R0)

465

0.630 (0.425–0.931)

0.021

  1. Significant values are in [bold].
Back to article page